Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2022 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
September 12, 2022 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...
May 11, 2022 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

NEWTOWN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
November 11, 2021 16:01 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

NEWTOWN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
September 24, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
September 22, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...